$0.62
14.15% today
Nasdaq, Apr 04, 09:20 pm CET
ISIN
US87978U1088
Symbol
TPST
Sector
Industry

Tempest Therapeutics Inc Stock price

$0.72
-0.06 8.19% 1M
-0.64 47.17% 6M
-0.12 13.90% YTD
-4.41 85.98% 1Y
-3.13 81.34% 3Y
-72.03 99.01% 5Y
-7,887.78 99.99% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.04 5.45%
ISIN
US87978U1088
Symbol
TPST
Sector
Industry

Key metrics

Market capitalization $32.68m
Enterprise Value $17.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.65
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.03m
Free Cash Flow (TTM) Free Cash Flow $-33.46m
Cash position $30.27m
EPS (TTM) EPS $-1.50
P/E forward negative
Short interest 4.37%
Show more

Is Tempest Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Tempest Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Tempest Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Tempest Therapeutics Inc forecast:

Buy
100%

Financial data from Tempest Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.39 0.39
76% 76%
-
-0.39 -0.39
76% 76%
-
- Selling and Administrative Expenses 13 13
54% 54%
-
- Research and Development Expense 28 28
62% 62%
-
-42 -42
51% 51%
-
- Depreciation and Amortization 0.39 0.39
76% 76%
-
EBIT (Operating Income) EBIT -42 -42
44% 44%
-
Net Profit -42 -42
42% 42%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tempest Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempest Therapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial • Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP)
Neutral
GlobeNewsWire
10 days ago
Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment
Neutral
GlobeNewsWire
22 days ago
BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer Prevention Clinical Trials Network received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate TPST-1495,...
More Tempest Therapeutics Inc News

Company Profile

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Head office United States
CEO Stephen Brady
Employees 25
Founded 2011
Website www.tempesttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today